Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. Social Networks
  11. External Links
  12. Analytics And Tracking
  13. Libraries
  14. Hosting Providers
  15. CDN Services

We began analyzing https://www.nature.com/articles/nrc3518, but it redirected us to https://www.nature.com/articles/nrc3518. The analysis below is for the second page.

Title[redir]:
Progesterone signalling in breast cancer: a neglected hormone coming into the limelight | Nature Reviews Cancer
Description:
Awareness is increasing that progesterone signalling via the progesterone receptor (PR) has important roles in breast biology and breast cancer. Understanding more about this pathway may lead to new therapeutic and preventive options for breast cancer. Understanding the biology of the breast and how ovarian hormones impinge on it is key to rational new approaches in breast cancer prevention and therapy. Because of the success of selective oestrogen receptor modulators (SERMs), such as tamoxifen, and aromatase inhibitors in breast cancer treatment, oestrogens have long received the most attention. Early progesterone receptor (PR) antagonists, however, were dismissed because of severe side effects, but awareness is now increasing that progesterone is an important hormone in breast cancer. Oestrogen receptor-α (ERα) signalling and PR signalling have distinct roles in normal mammary gland biology in mice; both ERα and PR delegate many of their biological functions to distinct paracrine mediators. If the findings in the mouse model translate to humans, new preventive and therapeutic perspectives might open up.

Matching Content Categories {📚}

  • Education
  • Science
  • Health & Fitness

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We're unsure if the website is profiting.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Doi.org might have a hidden revenue stream, but it's not something we can detect.

Keywords {🔍}

pubmed, google, scholar, cas, cancer, breast, mammary, progesterone, receptor, nature, gland, central, cells, development, cell, estrogen, mouse, hormone, signalling, therapy, study, expression, epithelial, article, mice, human, women, natl, res, brisken, access, proliferation, molecular, oestrogen, normal, postmenopausal, stem, content, paracrine, biol, sci, endocrinology, rank, cookies, function, steroid, hormonal, proc, risk, replacement,

Topics {✒️}

nature portfolio permissions reprints privacy policy experimental cancer research wnt/β-catenin-responsive stem cells middle-aged women advertising social media open α-smooth muscle actin post-natal mammary development nature rev transforming growth factor-β1 assessing reproductive status/stages author information authors progestin-driven mammary cancer estrogen receptor-α signaling triple-negative breast carcinomas nature 490 nature 486 nature 303 nature 406 nature 397 nature 465 nature 468 nature 479 nature 470 nature hormone-induced mammary tumors ccaat/enhancer binding protein increased epithelial proliferation alveolar epithelial cells competing financial interests springerlink instant access impairs alveolar differentiation permissions estrogen receptor α author apologizes author declares murine mammary gland personal data major regulatory axis oestrogen receptor-α epithelial progesterone receptor negative predictive factor mammary-gland development mammary gland development adult mammary epithelium early progesterone receptor mouse reproductive phenotypes

Questions {❓}

  • Intra-tumour heterogeneity: a looking glass for cancer?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Progesterone signalling in breast cancer: a neglected hormone coming into the limelight
         description: Awareness is increasing that progesterone signalling via the progesterone receptor (PR) has important roles in breast biology and breast cancer. Understanding more about this pathway may lead to new therapeutic and preventive options for breast cancer. Understanding the biology of the breast and how ovarian hormones impinge on it is key to rational new approaches in breast cancer prevention and therapy. Because of the success of selective oestrogen receptor modulators (SERMs), such as tamoxifen, and aromatase inhibitors in breast cancer treatment, oestrogens have long received the most attention. Early progesterone receptor (PR) antagonists, however, were dismissed because of severe side effects, but awareness is now increasing that progesterone is an important hormone in breast cancer. Oestrogen receptor-α (ERα) signalling and PR signalling have distinct roles in normal mammary gland biology in mice; both ERα and PR delegate many of their biological functions to distinct paracrine mediators. If the findings in the mouse model translate to humans, new preventive and therapeutic perspectives might open up.
         datePublished:2013-05-24T00:00:00Z
         dateModified:2013-05-24T00:00:00Z
         pageStart:385
         pageEnd:396
         sameAs:https://doi.org/10.1038/nrc3518
         keywords:
            Cancer microenvironment
            Cancer models
            Epidemiology
            Biomedicine
            general
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrc3518/MediaObjects/41568_2013_Article_BFnrc3518_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrc3518/MediaObjects/41568_2013_Article_BFnrc3518_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrc3518/MediaObjects/41568_2013_Article_BFnrc3518_Fig3_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrc3518/MediaObjects/41568_2013_Article_BFnrc3518_Fig4_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrc3518/MediaObjects/41568_2013_Article_BFnrc3518_Fig5_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrc3518/MediaObjects/41568_2013_Article_BFnrc3518_Fig6_HTML.jpg
         isPartOf:
            name:Nature Reviews Cancer
            issn:
               1474-1768
               1474-175X
            volumeNumber:13
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Nature Publishing Group UK
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Cathrin Brisken
               affiliation:
                     name:ISREC - Swiss Institute for Experimental Cancer Research, National Center of Competence for Molecular Oncology, School of Life Sciences, Ecole polytechnique fédérale de Lausanne (EPFL)
                     address:
                        name:ISREC - Swiss Institute for Experimental Cancer Research, National Center of Competence for Molecular Oncology, School of Life Sciences, Ecole polytechnique fédérale de Lausanne (EPFL), Lausanne, Switzerland
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Progesterone signalling in breast cancer: a neglected hormone coming into the limelight
      description: Awareness is increasing that progesterone signalling via the progesterone receptor (PR) has important roles in breast biology and breast cancer. Understanding more about this pathway may lead to new therapeutic and preventive options for breast cancer. Understanding the biology of the breast and how ovarian hormones impinge on it is key to rational new approaches in breast cancer prevention and therapy. Because of the success of selective oestrogen receptor modulators (SERMs), such as tamoxifen, and aromatase inhibitors in breast cancer treatment, oestrogens have long received the most attention. Early progesterone receptor (PR) antagonists, however, were dismissed because of severe side effects, but awareness is now increasing that progesterone is an important hormone in breast cancer. Oestrogen receptor-α (ERα) signalling and PR signalling have distinct roles in normal mammary gland biology in mice; both ERα and PR delegate many of their biological functions to distinct paracrine mediators. If the findings in the mouse model translate to humans, new preventive and therapeutic perspectives might open up.
      datePublished:2013-05-24T00:00:00Z
      dateModified:2013-05-24T00:00:00Z
      pageStart:385
      pageEnd:396
      sameAs:https://doi.org/10.1038/nrc3518
      keywords:
         Cancer microenvironment
         Cancer models
         Epidemiology
         Biomedicine
         general
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrc3518/MediaObjects/41568_2013_Article_BFnrc3518_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrc3518/MediaObjects/41568_2013_Article_BFnrc3518_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrc3518/MediaObjects/41568_2013_Article_BFnrc3518_Fig3_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrc3518/MediaObjects/41568_2013_Article_BFnrc3518_Fig4_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrc3518/MediaObjects/41568_2013_Article_BFnrc3518_Fig5_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrc3518/MediaObjects/41568_2013_Article_BFnrc3518_Fig6_HTML.jpg
      isPartOf:
         name:Nature Reviews Cancer
         issn:
            1474-1768
            1474-175X
         volumeNumber:13
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Nature Publishing Group UK
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Cathrin Brisken
            affiliation:
                  name:ISREC - Swiss Institute for Experimental Cancer Research, National Center of Competence for Molecular Oncology, School of Life Sciences, Ecole polytechnique fédérale de Lausanne (EPFL)
                  address:
                     name:ISREC - Swiss Institute for Experimental Cancer Research, National Center of Competence for Molecular Oncology, School of Life Sciences, Ecole polytechnique fédérale de Lausanne (EPFL), Lausanne, Switzerland
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Nature Reviews Cancer
      issn:
         1474-1768
         1474-175X
      volumeNumber:13
Organization:
      name:Nature Publishing Group UK
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:ISREC - Swiss Institute for Experimental Cancer Research, National Center of Competence for Molecular Oncology, School of Life Sciences, Ecole polytechnique fédérale de Lausanne (EPFL)
      address:
         name:ISREC - Swiss Institute for Experimental Cancer Research, National Center of Competence for Molecular Oncology, School of Life Sciences, Ecole polytechnique fédérale de Lausanne (EPFL), Lausanne, Switzerland
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Cathrin Brisken
      affiliation:
            name:ISREC - Swiss Institute for Experimental Cancer Research, National Center of Competence for Molecular Oncology, School of Life Sciences, Ecole polytechnique fédérale de Lausanne (EPFL)
            address:
               name:ISREC - Swiss Institute for Experimental Cancer Research, National Center of Competence for Molecular Oncology, School of Life Sciences, Ecole polytechnique fédérale de Lausanne (EPFL), Lausanne, Switzerland
               type:PostalAddress
            type:Organization
PostalAddress:
      name:ISREC - Swiss Institute for Experimental Cancer Research, National Center of Competence for Molecular Oncology, School of Life Sciences, Ecole polytechnique fédérale de Lausanne (EPFL), Lausanne, Switzerland
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

Social Networks {👍}(2)

External Links {🔗}(407)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Prism.js
  • Zoom.js

Emails and Hosting {✉️}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {📦}

  • Crossref

4.61s.